Core Insights - Ensysce Biosciences, Inc. (ENSC) stock experienced a nearly 100% increase in value, with significant trading volume surpassing the average of 81.23K shares [1] - The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to Enzyme-Cleavable Methadone Prodrugs, which includes claims for both composition and methods of use [1] Group 1: Product Development and Clinical Trials - PF9001, the medication associated with the new patent, aims to provide a safer treatment for opioid use disorder (OUD) utilizing Ensysce's TAAP and MPAR technologies for abuse deterrence and overdose protection [2] - Methadone has been traditionally used for OUD, but its application has been limited due to concerns about cardiac side effects and overdose risks [3] - Ensysce has developed PF9001, which shows reduced cardiotoxicity and validates the MPAR technology for overdose protection, with indications of a prolonged effect from once-daily dosing [3] Group 2: Clinical Trial Results - The National Institute on Drug Abuse supported the research for the patent, and Ensysce completed Part 1 of its second clinical trial for PF614-MPAR, which demonstrated effective overdose protection while relieving severe pain [4] - The trial confirmed that a 100 mg dosage of PF614-MPAR provides overdose protection when doses exceed the prescribed amount, showing reduced maximum oxycodone release compared to PF614 alone [5] - Safety data from the trial indicated no unexpected adverse events, and the study will continue to evaluate food effects and repeat dosing [6] Group 3: Financial Activities - Ensysce Biosciences announced a registered direct offering of approximately $1.1 million in March, issuing 315,188 shares at a price of $3.49 per share [7] - Following the news, ENSC stock rose by 96.30%, reaching a price of $3.67 [7]